Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT00609817 is registered in ClinicalTrials.gov with La Jolla Pharmaceutical Company as lead sponsor.

NCT NCT00609817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00609817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Lead sponsor
La Jolla Pharmaceutical Company
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2008
Completion date
April 30, 2009
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma